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Introductory Note 
The milestones in the following material were discussed at a historical consensus 
conference held at the University of California, Los Angeles (UCLA) to which 11 early 
workers in transplantation were invited: Leslie B. Brent (London), Roy Y. Caine 
(Cambridge, UK), Jean Dausset (Paris), Robert A. Good (St. Petersburg. USA), 
Joseph E. Murray (Boston). Norman E. Shumway (Palo Alto). Robert S. Schwartz 
(Boston), Thomas E. Starzl (Pittsburgh), Paul I. Terasaki (Los Angeles), E. Donnall 
Thomas (Seattle) and Jon J. van Rood (Leiden). Each person provided personal 
reflections which have been published in a special issue of the World Journal 0 
Surgery (2000, Vol. 24: 755-843). However, the ultimate objective was to reach 
consensus on the key historical discoveries prior to 1975 that eventually allowed 
clinical transplantation to become a feasible and practical form of therapy. Carl Groth 
of Stockholm was invited to be the Chairman for these consensus deliberations, and 
to prepare the executive summary (1). Consensus landmarks in the summary were 
restricted to those made at least a quarter of a century ago. Although advances in the 
1975-2000 period were not formally reviewed, the ones alluded to here appear 
destined for milestone status. 
The concept of transplanting animal or human tissues and organs to patients is 
almost as old as recorded history (2). However, the first enduring contribution was the 
technology of blood vessel anastomosis developed by Carrel (3) (see Table I). Carrel 
recognized that transplanted organ allografts and xenografts were not permanently 
accepted, although he did not know why. 
Table I: Nobel Prizes related to immunologyltransplantation. 
Year Name Accomplishment 
1901 Emil Adolf Von Behring Discovery of antibodies 
1905 Heinrich Hermann Robert Cause and effect of microorganisms and infection 
Koch 
1908 lIya Metchnikoff Champion of cellular immunity 
Paul Ehrlich Side chain (receptor) concept; antimicrobial therapy 
Champion of humoral immunity 
1912 Alexis Carrel Vascular surgery and transplantation 
. - . - .. 
-
_. 
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1919 Jules Bordeau Discovery 01 complement 
1930 Karl Landsteiner Discovered ABO blood group antigens 
1960 Sir Frank MacFarlane Clonal selection hypothesis 
Burnet Acquired transplantation tolerance 
Sir Peter Brian Medawar 
1972 Gerald M. Edelman Characterized immunoglobulins 
Rodney R. Porter Clarified structure of antibody molecule 
1980 Baruj Benacerrat Discovered immune response genes 
Jean Dausset Discovered first HLA antigen 
George Davis Snell Discovery of major histocompatibility complex 
(MHC) in mice 
1984 Niels Kaj Jerne Important immunologic hypotheses 
Georges J.F. Kohler Hybridoma technology 
Cesar Milstein Hybridoma technology 
1985 Michael Stuart Brown Hepatic control of cholesterol metabolism 
Joseph Leonard Goldstein 
1987 Susumu Tonegawa Discovered somatic recombination of immunologic 
receptor genes 
1988 Gertrude Belle Elion Co-discovered 6-MP and azathioprine 
George Herbert Hitchings 
1990 Joseph E. Murray Kidney transplantation 
E. Donnall Thomas Bone marrow transplantation 
1996 Rolf Zinkernagel Co-discovered the role of MHC restriction in 
Peter C. Doherty adaptive immune response to pathogens 
Source: Nobel Foundation, Stockholm. 
The Technical Challenge 
The kidney 
Attempts at clinical renal xenotransplantation by vascular anastomoses were 
undertaken at the beginning of the 20th century in France and Germany using pig, 
sheep, goat and subhuman primate donors. None of the kidneys functioned for long, 
if at all, and the unmodified human recipients died a few hours to 9 days later. No 
further clinical xenotransplantations were tried again until chimpanzee (4) and baboon 
kidney xenografts were transplanted to human recipients under immunosuppression 
(5). 
The first known attempt at transplantation of an organ allograft was reported from 
Kherson (the Ukraine) in 1936 by Yu Yu Voronoy (6); an English translation of the 
article was provided by Hamilton and Reid (7). The kidney, which was removed from 
a cadaver donor, never functioned. This was not surprising in view of multiple adverse 
factors: ABO incompatibility between the donor and recipient, a 6-hour delay at room 
temperature between donor death and kidney removal, and the recent suicide attempt 
of the recipient by mercury ingestion. In 1951, systematic clinical trials of kidney 
allotransplantation in unmodified human recipients were undertaken in France by 
Kuss, Teinturier and Milliez (8), Dubost et al. (9), and Servelle, Soulie, and Rougeulle 
(10). Most of the kidneys were obtained from criminals immediately after their 
execution by the guillotine, and some briefly excreted urine. 
The first live donor kidney transplantation was performed in Paris by Michon et al. 
(11), using the extraperitoneal pelvic procedure developed by Kuss. This mother-to-
son transplantation resulted in prompt kidney function that continued for 3 weeks 
before the allograft was rejected by the unmodified reCipient. Kuss's procedure has 
been used worldwide ever since with an outstanding record of safety and reliability. 
In the meantime, nine kidney allotransplantations were performed between March 30, 
1951, and December 3, 1952, in patients whose pre- and post-transplantation dialysis 
was at the Peter Bent Brigham Hospital (liThe Brigham") in Boston (12). In the first of 
these operations, pe~orD:lKed .. by L.H. Doolittle in Springfield, M~ss~chusettsI the 
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allogran was transplantea to me vacatea renal rosa or me reCIpient aner removal or 
the native organ. The next eight transplantations were performed at the Brigham. All 
eight of these allografts were placed by David Hume in the recipient anterior thigh. 
Some of the recipients received adrenal cortical steroids, and one of the transplanted 
kidneys produced urine for 5 months. 
In December 1954, kidney transplantation from an identical twin donor recipient was 
carried out by Joseph E. Murray at the Brigham Hospital in Boston (13, 14). It was 
known from earlier research by plastic surgeons that skin grafts from identical twins 
were not rejected. To test genetic identity, reciprocal skin grafting was carried out 
prior to the kidney transplantation. Despite 82 minutes of warm ischemia, the isograft 
functioned immediately and for the next 25 years, until the death of the recipient from 
atherosclerotic coronary artery disease. Although the identical twin kidney 
transplantations did not provide fundamental new information about transplantation 
immunology, the cases exemplified the potential power of transplantation. 
The extrarenal organs 
Using vascular surgical techniques, animal research in transplantation was most 
highly focused on the kidney for most of the first half of the 20th century. The 
extrarenal vacuum rapidly was filled between 1958-1960 with the development in 
several laboratories of canine models with which to study all of the intra-abdominal 
and thoracic organs. Although each organ presented specific technical and 
physiologic issues, the core problems of immunosuppression, tissue matching and 
allograft preservation eventually were worked out mainly with the kidney and/or the 
liver and applied to other organs with minor modifications. 
The Seminal Turning Points 
The modern history of transplantation could be written from the vantage point of the 
first successful use in humans of allografts of the various organs and of bone marrow 
(Table II). However, a more accurate and complete picture can be obtained by 
reviewing how it was learned to harness destructive immunity enough to allow 
allograft survival. After Medawar's demonstration that rejection is an immune reaction 
(15), the feasibility of transplanting allografts hinged on two observations. The first 
was the discovery in 1953 by Billingham, Brent and Medawar (16, 17) that chimerism-
associated neonatal tolerance could be induced in intrauterine and neonatal mice by 
the infusion of donor hematolymphopoietic cells (i.e., splenocytes and bone marrow). 
The second seminal turning point was the recognition that human organ allografts 
were inherently tolerogenic when transplanted to immunosuppressed recipients (18). 
Table II: First successful transplantation of human allografts (survival> 6 months). 
~rgan City Date Physician/Surgeon 
Kidney Boston January 24, 1959 Murra~ et al. (36t 
Bone marrow Paris April 23, 1963 Mathe et al. (28) 
Liver Denver July 23, 1967 Sta rzl et al. (711 
Heart l-ape Town January 2, 1968 Barnard (131L 
Pancreas· Minnea~olis ,June 3, 1969 Lillehei et al. (132) 
Lung·· [ghent November 14, 1968 Derom et al. (133) 
Abdominal multivisceral··· Pittsburgh November 1,1987 Starzl et al. (134) 
Intestine alone Paris March 18, 1989 K30ulet et al. (135) 
·Kldney and pancreas allografts in uremic patient. ··Patient died after 10 months. The 
first> 1-year survival of isolated lung reCipient was not reported until 1987 (136). 
···Small and large bowel plus liver, pancreas, stomach and duodenum. The patient died 
after 6 months. 
Unfortunately, these two sets of observations led to a Y in the road, beyond which 
successful engraftment of bone marrow was explained by donor leukocyte 
chimerism-dependent mechanisms, as opposed to organ engraftment, which was 
attributed to chimerism-independent mechanisms. This egregious error precluded 
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genuine Inslgnt Into me Immunology OT tranSplantation Tor nearly tnree decades and 
resulted in a systematic misinterpretation of research studies in transplantation (19). 
That a mistake of such magnitude could have been perpetuated for so long without a 
single challenge in the scientific literature is truly remarkable. This can be explained in 
part by the primitive state of immunology (see next section) at the time the false 
dogma became imbedded in the scientific literature and textbooks. 
The Ascendancy of Immunology 
The foundation of immunology had been laid at the turn of the century by the 
piecemeal discovery of the different components of the immune response and of the 
role of immunity in the defense against infectious disease. This wave of advances 
resulted in a large proportion of the first 30 Nobel prizes (Table I). The big leaps were 
succeeded by a period of "consolidation" that was reflected by a gap of 30 years 
between the 1930 Nobel prize for Landsteiner's discovery of ABO groups and the 
1960 prize which was awarded to Burnet and Medawar (see Table I). Burnet with 
Fenner (20) had initially postulated that an individual produced antibodies only to 
those antigens to which (s)he had been exposed. Over the next decade, this clonal 
selection hypothesis was validated and extended by Burnet (21) to cellular immunity, 
thus providing a conceptual framework for the ontogeny of the immune system as 
well as for its function. 
An important supporting strut in Burnet's hypotheses was the earlier study by Owen 
(22) of freemartin cattle, the bovine equivalents of human fraternal twins. Owen 
observed that permanent hematopoietic chimerism developed reciprocally in calves 
whose placentas had fused, thereby allowing intrauterine circulatory exchange. 
Working with Medawar, Anderson et al. (23) subsequently showed that these cattle 
also had reciprocal tolerance to skin grafts. The authors speculated that actively 
acquired tolerance could be induced deliberately by mimicking the conditions of cross 
circulation. When the neonatal tolerance experiments of Billingham, Brent, and 
Medawar (16,17) upheld the prediction, the observations were viewed as formal proof 
of the clonal selection theory of Burnet. 
The Billingham-Brent-Medawar Experiments 
In the original Billingham-Brent-Medawar experiments (16), acquired tolerance to skin 
allografts was induced in fetal and neonatal mouse recipients whose immunologically 
immature immune system was unable to reject the infused splenocytes from adult 
donors. In later experiments, bone marrow cells were used (17). The inoculated 
animals that survived to adult life had circulating donor leukocytes and developed 
specific nonresponsiveness to donor strain skin allografts, while evolving normal 
reactivity to third-party grafts. By 1957, however, it had been learned that the 
engraftment of immunocompetent donor leukocytes in immunologically defenseless 
reCipients caused graft-versus-host disease (GVHD) that was avoidable or 
controllable only when there was a close genetic relationship between donor and 
recipient (i.e., a good tissue match) (24-26). 
In a logical extension of these experiments, adult mice were preconditioned for bone 
marrow transplantation with supralethal total body irradiation [TBI]). With engraftment 
of the donor bone marrow cells in these animals, the result was the same in principle 
as that achieved a decade later with human bone marrow transplantation to 
cytoablated recipient. However, the requirement for a good tissue match in mice (27) 
applied equally to humans (28-30). Mathe was the first to achieve prolonged survival 
after engraftment of allogeneic human bone marrow cells, but in spite of good 
histocompatibility between multiple familial donors and the cytoablated reCipient, 
chronic graft-versus-host disease (GVHD) developed in this patient and caused his 
death after 2 years. Finally, in 1968, bone marrow cells were successfully 
transplanted from familial donors into two recipients whose immune deficiency 
diseases made cytoablation unnecessary (29, 30). Both patients are alive and well 32 
years later. 
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Immunosuppression for Organ Transplantation 
Once rejection was identified by Medawar (15) as an immunological event, 
weakening the recipient response with TBI or with immunosuppressive drugs, 
became a logical strategy for mitigating or preventing the immune reaction. Cortisone, 
which did not depress bone marrow, was the first drug to prolong the survival of rabbit 
skin allografts (31), but the effect was modest. In contrast, observations in chickens 
reported by Cannon and Longmire (32) were of exceptional significance. However, 
the importance of this work was not recognized until many years later. 
In control experiments, Cannon and Longmire showed that freshly hatched chicks 
permanently accepted skin allografts from different adult breeds in 6% of 
experiments. When a course of cortisone treatment was given, this incidence rose to 
over 20% without an increased mortality. The critical observation was that the skin 
allograft survival was of lifetime duration, i.e., continued after discontinuance of the 
steroid course. This finding presaged the discovery in Denver a decade later that 
organs were inherently tolerogenic in patients treated with azathioprine and dose-
maneuverable prednisone (18). Because the Cannon/Longmire studies had been 
long since passed over, however, they did not alter the pessimistic attitudes prevalent 
at the time about the feasibility of clinical organ transplantation. 
Total body irradiation (TBI) 
Instead, it was widely believed by the late 1950s that successful organ transplantation 
would not be possible without establishing donor leukocyte chimerism by the 
concomitant or preceding engraftment of donor bone marrow cells as had been 
shown to be feasible in cytoablated mice (27, 33). In practice, this approach proved to 
be impossible in large outbred animals (34). With the dog model, only a single 
irradiated beagle recipient survived for as long as 70 days following combined bone 
marrow and kidney transplantation (35). 
Despite this discouraging record in animals, Murray et al. attempted the combined 
procedure at the Peter Bent Brigham Hospital (Boston) in two TBI-conditioned 
patients, both of whom died in less than a month. The next 10 human recipients in 
this trial were conditioned in 1958-60 with sublethal total body irradiation (TBI), 
followed by kidney transplantation alone (36, 37). All but one of the patients also died 
within 1 month. In the exceptional case, however, the irradiated recipient of a fraternal 
twin kidney survived for more than 20 years before dying of a malignant tumor. It was 
the first example in the world in any speCies including humans of successful organ 
transplantation from a genetically nonidentical donor. 
It was suspected initially that placental fusion and cross circulation between the twins 
may have occurred in utero (as with Owen's freemartin cattle). The same reservation 
pertained to a second extended survival following fraternal twin kidney transplantation 
in Paris 5 months later (38). In the succeeding 3 years, however, the issue was 
settled by 4 more examples of survival ;::: 1 year in Paris. Two of these irradiated 
patients received kidneys from non-twin family members (39). The kidneys in the 
other 2 cases were from non-related donors (40)(Table III). Because none of the 6 
kidney allograft reCipients who had ;::: 1 year survival had been given adjunct donor 
bone marrow cells, it was concluded that donor leukocyte chimerism was not a 
necessary condition for successful kidney transplantation. 
Table III: Kidney transplantation <?6 months' survival as of March 1963. 
Case (reference) City Date Donor Survival (months)+ 
1 (36. 137) Boston January 24. 1959 Fraternal twin >50 
2 (38, 39) Paris June 29, 1959 Fraternal twin >45 
':\ lAm m~ri~ IlIno?? 1~n I Inrol'!llh::ali* 1 A IAicu"n 
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4 (38, 39) Paris December 19,1960 Mother' 12 (died) 
5 (40) Paris March 12, 1961 Unrelated" 18 (died) 
6 (38, 39) Paris February 12, 1962 Cousin' >13 
7 (36, 137) Boston Apri15,1962 Unrelated 10 
'Adjunct steroid therapy. +The kidneys in patients 1,2 and 6 functioned for 20.5,25 and 
15 years, respectively. Patient 7 rejected his graft after 17 months and died 7 months 
after return to dialysis. 
Pharmacologic immunosuppression 
Because the failure rate using TBI was overwhelming, the prospects for developing 
kidney transplantation as a clinical service remained grim until the end of 1962. A sea 
change began with the testing of drugs whose myelotoxicity initially prompted their 
use as a substitute for TBI. In 1963, Willard Goodwin of Los Angeles belatedly 
reported a case of a mother-to-daughter kidney transplantation that had been carried 
out in September 1960, after first producing severe bone marrow depression with 
large doses of methotrexate and cyclophosphamide. During the 143 days of survival, 
the recipient developed several rejections that were reversed with prednisone (41). 
Although this was the first example of extended survival of a human kidney recipient 
without the use of TBI, the case did not significantly impact the field because its 
existence was not generally known. In the meanwhile, it was learned in studies of 
rabbit skin transplantation (42, 43) and of kidney transplantation in dogs (44-46) that 
the drug 6-mercaptopurine (6"MP) and its imidazole derivative azathioprine, were 
immunosuppressive at submyelotoxic doses. Both agents permitted only about 5% 
long-term survival of canine kidney allografts (37), but the transplanted kidneys in 
some of the long-surviving animals continued to function long after discontinuance of 
immunosuppression (47-50). The observation was reminiscent of the finding in newly 
hatched chicks treated with a short limited course of cortisone that had been 
described a decade earlier (32). 
Realizing that neither 6-MP nor azathioprine alone would permit more than an 
occasional clinical success, Caine and Murray (51) tested azathioprine in combination 
with other myelotoxic drugs at the Brigham canine laboratory. Prompted by the 
personal communication from Goodwin about the effect of steroid therapy (52), 
prednisone was also added to azathioprine. When the azathioprine-prednisone 
combination appeared to be no more effective than azathioprine alone (45, 53), the 
decision was made to use azathioprine with the myelotoxic agents azaserine and 
actinomycin for the Boston clinical trials. Only one of the first 10 drug-treated kidney 
reCipients survived. The exceptional patient received a non-related kidney on April 5, 
1962, and remained dialysis-free for 17 months until the allograft was lost to chronic 
rejection. Thus, this patient became the seventh 1-year kidney allotransplant survivor 
in the world. More importantly, he was the first to achieve this milestone without TBI 
(Table III). 
With the low rate of success, however, kidney transplantation was still viewed with 
pessimism. This was relieved by two observations at the University of Colorado, first 
in canine kidney recipients and then in a series of 10 consecutive human cases 
compiled in 1962-63. The addition of high doses of prednisone to baseline therapy 
with azathioprine resulted not only in reversal of established rejection, but also in the 
variable induction of donor specific tolerance (18). Nine of the 10 human recipients 
had prolonged survival and 2 remain alive today with excellent function of their 
original grafts in their 38th post-transplant year. These 2 patients (cases 2 and 3 in the 
original series), who bear the longest continuously functioning allografts in the world, 
have been free of all immunosuppression for 5 and 36 years respectively. 
These results, and especially the easily taught treatment principles with which they 
were accomplished, fostered a whirlwind of activity in the United States and Europe. 
While dozens of new kidney transplant centers were established, the mechanisms by 
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which the allografts had been "accepted" remained unknown. However, the 
conclusions that the kidney allografts had induced variable donor-specific tolerance, 
and that engraftment depended on alterations in the transplanted organ plus a loss of 
specific responsiveness by the recipient (18, 49) has stood the tests of time and of 
experimental verification. 
These conclusions continued to generate controversy for three decades. 
Commenting on mechanisms, Medawar (54) suggested that a progressive 
replacement of the vascular endothelium of the graft vessels by endothelium of host 
origin may have been made possible by weakening the allograft reaction with 
immunosuppression. Neither this hypothesis nor the suggestion that "a protective" 
host antibody had come to cover the endothelial layer (attributed to Caine by 
Medawar [54]) has proved to be correct. 
The enigmatic phenomena of the reversal of rejection and the development of 
variable donor-specific tolerance observed after kidney transplantation were soon 
demonstrated with other organs. Furthermore, canine recipients of orthotopic liver 
allografts self-induced tolerance under short-term azathioprine therapy much more 
frequently than renal allografts (55). Soon thereafter, examples of spontaneous 
engraftment and self-resolving rejection crises in the absence of treatment were 
reported following liver transplantation in untreated outbred pigs (56-58). 
Spontaneous tolerance has since been demonstrated in rats (59, 60) and mice (61). 
Eventually, it was shown that heart (61, 62) and kidney allografts (63) could also self-
induce donor-specific tolerance in selected mouse strain combinations. Exhaustion 
and deletion of an antigen-specific clone was one of the mechanisms proposed for 
allograft acceptance as early as 1964 and again in 1969 (Fig. 1), but this was difficult 
to defend in the absence of chimerism. The failure to evolve an intellectual framework 
with which to explain organ engraftment contrasted with bone marrow transplantation 
in which the association of tolerance with donor leukocyte chimerism was readily 
apparent. 
___ .. -'" # <:Jcca 
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Fig. 1 
Thus, organ transplantation became disconnected from a scientific base, creating an 
image that was judged at times to be dubious--scientifically, ethically and practically. 
A widely-expressed opinion was that chronic immunosuppression would lead 
inevitably to lethal infectious complications and/or the development of malignant 
tumorsg~i~IK 2). ,These complications did, in fact, prove to be c~mmon: Infection was 
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exemplitied by the cytomegalovirus (CMV), which normally has low pathogenicity, but 
which has been responsible for many post-transplantation deaths as a coinfection 
with Pneumocystis carinii. De novo neoplasms, and particularly the Epstein Barr 
virus-associated B-cell malignancies, were prototype examples of the loss of tumor 
surveillance (64). As it turned out, these problems were manageable. 
Fig. 2 
Antilymphoid strategies 
Successful kidney transplantation was first accomplished several years before the 
lymphocyte had any known function, and almost a decade before the distinction 
between T- and B-Iymphocytes was made. After Gowan"s studies in rats 
demonstrated the defects in the immune response caused by lymphoid depletion with 
thoracic duct drainage (TOO) (65, 66), TOO was used in Stockholm in 1963 and 
subsequently to precondition human kidney recipients (67). Although moderately 
effective, TOO was inconvenient and expensive. When Woodruff and Anderson (68) 
added antilymphocyte serum (ALS) to TOO, the effects were additive, but this 
combination was never used clinically. 
In 1966, heterologous antilymphocyte globulin (ALG) was introduced clinically for 
lymphoid depletion (69). In preclinical studies, horse anti-dog antilymphocyte serum 
(ALS) was raised and the active component was shown to be a gamma globulin 
moiety (70). After demonstrating that the refined horse anti-dog ALG inhibited or 
reversed kidney and liver rejection in dogs, horse anti-human ALG was raised and 
given to human kidney recipients as a short-term adjunct to azathioprine and 
prednisone. After the "triple drug" therapy was shown to be effective in the kidney 
trial, the same treatment was used in 1967 for the first successful liver 
transplantations (71). 
Within 24 months after the first successful liver replacement, many extrarenal 
transplant programs (i.e., heart, lung and pancreas) were begun, using triple drug 
therapy. Although isolated successes were recorded (Table II), most of these new 
programs closed because of the high mortality. Nevertheless, ALG played an 
important role in the first successful extrarenal organ transplant procedures and 
served as the therapeutic model for strategies using the more standardized antibody 
preparations made possibly by the hybridoma technology of Kohler and Milstein (72). 
OKT3, a monoclonal antibody directed against all T-Iymphocytes was introduced 
clinically in the early 1980s (73) and is still part of the immunosuppressive 
armamentarium. Other monoclonal antibody preparations have been developed more 
. . . . .. . . . 
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recently, some ot which are humanized hybrids and directed at such diverse targets 
as T-cell subsets, adhesion molecules and receptors for T-cells or interleukin-2 (IL-2). 
Their diversity notwithstanding, the use of all of the monoclonal antibodies is guided 
by the same treatment principles that were developed with the crude ALG. 
T -Cell Directed Drugs 
Borel et a/. (74) showed that cyclosporine depressed cellular immunity by acting with 
relative specificity on T-Iymphocytes without depressing the bone marrow and without 
obvious toxicity to other organs. Borel et al. also reported that the new drug prolonged 
skin allograft survival in mice, rats and guinea pigs. Kostakis et al. (75), Caine and 
White (76) and Green and Allison (77) then demonstrated that cyclosporine could 
prevent or delay heart, kidney, liver or pancreas rejection in rats, rabbits, dogs and 
pigs. After cyclosporine was introduced clinically, the dose-limiting nephrotoxicity of 
the drug became apparent as well as its neurotoxicity, diabetogenicity, cosmetic side 
effects and propensity to induce B-cell lymphomas (78, 79). At lower doses, and in 
combination with prednisone (80), the prognosis with transplantation with all kinds of 
organs, and especially the liver (81), was dramatically improved (Fig. 3). 
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Tacrolimus was first used clinically as a replacement for cyclosporine in patients who 
were intractably rejecting liver allografts (82, 83). When the drug was found to rescue 
>75% of rejecting hepatic allografts and other kinds of rejecting organs, trials began 
using tacrolimus as the baseline agent from the outset (84). Tacrolimus did not have 
cyclosporine's cosmetic side effects, but the nephrotoxicity, neurotoxicity and 
diabetogenicity profiles were similar. As with cyclosporine, these problems were dose-
related and manageable by using tacrolimus in combination with prednisone or in 
more complex drug cocktails. Survival of various kinds of grafts and their reCipients 
was improved (Fig. 3) and it became possible for the first time to offer intestinal 
transplantation as a clinical service (85). Most recently, tacrolimus has been 
combined with rapamycin, with unprecedented control and prevention of rejection. 
Organ Preservation 
Very little research had been done on preservation of organs at the time clinical 
kidney transplantation suddenly and unexpectedly became a widely used form of 
treatment in the early 1960s. Total body hypothermia of live donors was used initially 
+,.., ___ i.."i ........ , __ jI~IKKhIKII ___ i_ inill'-" +n +h_ ,""v,..i",,,,,... L,.i,...,.",,,,,, loa\ hl.+ +hi,.. __ .. "" ..... +i_"" ,., .......... ,...,."." •• ro. 
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practice was promptly supplanted by infusion of chilled fluids into the allograft renal 
artery immediately after donor nephrectomy (87). Intravascular cooling of liver 
allografts with chilled lactated Ringer's solution had been developed much earlier in 
canine liver transplant experiments and had dramatically increased the chance of 
survival (88). Today, intravascular cooling derived from the in situ techniques of 
Marchioro et al. (89) remains the first step in the preservation of all cadaveric organs. 
Two basic strategies for extending organ graft survival after initial cooling were also 
developed with kidneys and livers, and applied to other organs. In one, ex vivo 
perfusion techniques were used to simulate normal physiologic conditions as 
pioneered by Carrel and Lindberg (90). Using blood for priming, the technology was 
modified by Ackerman and Barnard (91). Because these perfusion methods were too 
complex for general use, Belzer, Ashby and Dunphy (92) developed a simplified 
asanguinous perfusion technique, which eventually was abandoned in favor of the 
second option of "slush" preservation. 
Slush preservation consists of intravascular infusion with chilled fluids, followed by 
immersion of the organ in the fluid and simple refrigeration. Collins, Bravo-
Shugarman and Terasaki (93) replaced the original lactated Ringer's solution with a 
perfusate that resembled the electrolyte composition of intracellular fluid. Renal 
allograft preservation with the "Collins solution" was reliable for at least a day, and 
preservation of the liver was adequate for approximately 6 hours. Nearly 20 years 
passed before the advent of the University of Wisconsin (UW) solution allowed the 
safe preservation of livers for 24 hours (94, 95) with a doubling of the safe time for 
kidney preservation. The UW solution made the exchange of organs between 
different cities or countries a reality. 
Before 1980, cadaveric organ procurement and kidney procurement were essentially 
synonymous. With the emergence of extrarenal organ transplantation, flexible 
techniques were developed with which the kidney, liver, heart, lung, pancreas and 
even intestine could be removed separately or in combinations (96, 97). These 
flexible techniques involve cooling of all organs in situ and removal in a bloodless 
field, followed by ex vivo dissection. Taken together, the improvements in organ 
procurement and preservation have allowed the efficient use of donor organs, an 
especially important advance in view of the world-wide shortage of essentially all 
kinds of allografts. 
Immunologic Screening 
Matching cadaveric donors against a list of prospective recipients was not possible 
until effective methods of organ preservation became available. Consequently, it had 
been predicted in the early 1960s that tissue matching and organ preservation would 
have to develop in parallel if long-term engraftment of tissues and organs was to 
succeed with any degree of reliability and predictability. Instead, immunologic 
screening of donors and recipients played a very little role in the developmental 
period of organ transplantation during the volatile period of 1959-1968. 
The crossmatch principle 
As it turned out, the greatest impact of pretransplant immunologic screening has been 
the prevention of hyperacute rejection by observation of ABO compatibility guidelines 
and the routine use of the cytotoxicity crossmatch. 
ABO incompatibility. Hyperacute rejection was first observed more than 30 years ago 
when ABO-mismatched renal allografts were transplanted into patients who had 
preformed antigraft ABO isoagglutinins (98). After such kidneys were lost on the 
operating table, arteriograms of the infarcted organs showed nonfilling of the small 
vessels. The gross findings correlated histopathologically with widespread thrombotic 
occlusion of the microvasculature. 
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It was concluded that high-affinity ABO isoagglutinins in the recipient sera had bound 
to A or B antigens in the graft vessels and parenchymal cells. The guidelines 
formulated from this experience (Table IV) were designed to avoid such antibody 
confrontations (98). The ABO rules also apply to heart, liver, and other kinds of organ 
transplantation. However, not all organs placed in an environment made hostile by 
antigraft isoagglutinins meet the same fate. In addition, it was learned at an early time 
that the liver is more resistant to antibody attack than other organs (99). 
Table IV: Direction of acceptable organ transfer when the donor and recipient have different ABO red cell types 
(98) .• 
o to non-O Safe 
Rh- to Rh+ Safe 
Rh+ to Rh- Relatively safe 
A to non-A Dangerous 
B to non-S Dangerous 
AS to non-AS Dangerous 
"For organ transplantation, 0 is universal donor and AS is universal recipient. With the 
transplantation of bone marrow allografts, or of lymphoid-rich organ allografts (e.g., 
intestine or liver), enough anlihost isoagglulinins may be produced by the allograft 10 
cause serious or lethal hemolysis in a significant number of cases (humoral GVHD). 
Consequently, the rules summarized in this table are fully applicable only with leukocyte-
poor organs like the kidney and heart. 
Preformed antidonor cytotoxins. Hyperacute rejection of a kidney by an ABO 
compatible recipient was reported for the first time by Terasaki, Marchioro and Starzl 
(100). Terasaki's observation that the serum of the recipient of a live donor kidney 
contained preformed antigraft Iymphocytotoxic antibodies was promptly confirmed in 
similar cases by Kissmeyer-Nielsen et al. (101) and by others (102, 103). The 
evidence of a cause and effect relation in Terasaki's single first case was so clear 
that he recommended and immediately introduced his now universally applied 
Iymphocytotoxic crossmatch test (100, 104). 
Tissue matching 
The importance of the genetically determined major histocompatibility complex (MHC) 
in determining the immune response to allografts was established at a very early time 
by investigations in inbred mice (105, 106). The possibility of clinical tissue matching 
did not begin to emerge, however, until the discovery of the first human leukocyte 
antigen (HLA) (107), and the discovery in the same year of antileukocyte antibodies 
(soon shown to be HLA directed) in the sera of pregnant women (108). 
The report in 1964 of the microcytotoxicity test, with which HLA antigens could be 
detected serologically with minute quantities of sera (109) was a further critical 
development in moving forward with the detection and classification of the antigens. It 
was anticipated that long-term organ engraftment would be achievable only with a 
high degree of donorlrecipient HLA match, and that there would be a stepwise 
deterioration in outcome with every level of HLA mismatch. The importance of HLA 
matching was immediately fulfilled with bone marrow transplantation, in which 
anything less than a perfect or near perfect match between the donor and recipient 
resulted in GVHD or else rejection of the graft (28-30,110). 
Inexplicably at the time, Terasaki promptly recognized that kidney transplantation was 
not dependent on tissue matching. This was evident in a retrospective study of long-
surviving kidney recipients and their volunteer live donors (111), This was followed by 
a prospective trial in which kidney donors were selected on the basis of the best 
available HLA match for recipients who were treated with azathioprine and 
prednisone, with or without adjunct ALG (112). Although HLA-matched (zero 
mismatched) alloQrafts had the best survival and function, no cumulative adverse 
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effect of mismatching in the kidney recipients could be identified (113). This imprecise 
prognostic discrimination also pertained to cadaver kidney transplantation (114) and 
has been evident in analyses up to the present time. The absence of a large and 
consistent matching effect unless there is a perfect or near perfect match has always 
been the same (115). Furthermore, the difference in clinical outcome with completely 
matched versus variably HLA-mismatched allografts has been surprisingly small. 
Terasaki's observations of the University of Colorado kidney cases nearly three 
decades ago breathed life into the still struggling fields of liver, heart and lung 
transplantation. It was a relief to know that the selection of donors with random tissue 
matching would not result in an intolerable penalty. A quarter of a century passed 
before it could be explained why HLA matching was critical for bone marrow, but not 
organ, transplantation (see next section). 
Allograft Acceptance and Acquired Tolerance Involve the Same Mechanisms 
Until the last decade, a transplanted organ was viewed as a defenseless object of 
immune attack by the host, subject to rejection of varying severity depending on the 
degree of histoincompatibility (Fig. 4, upper left). In contrast, the cytoablated host 
after bone marrow engraftment was viewed as the defenseless object of a 
unidirectional graft-vs.-host (GVH) immune reaction (Fig. 4, upper right). In the early 
1990s, we discovered evidence suggesting that both of these perceptions were 
incorrect in that a double immune reaction occurred with both kinds of transplantation. 
This insight began with a study of long-term human survivors of liver, kidney and 
other organ transplantations. 
It was discovered that all of these organ recipients had small numbers of donor 
leukocytes in their blood or tissue (microchimerism) (116-118). At about the same 
time, it was shown that cytoablation of bone marrow recipients does not completely 
destroy host leukocytes (119, 120) as had been previously assumed. From these 
findings, we concluded that a bidirectional immune reaction had taken place in both 
bone marrow and solid organ recipients , and that this occurred with maximum 
intensity in the first few post-transplant days or weeks (Fig. 5). The differences 
between organ transplantation and bone marrow transplantation (Table V), which had 
been assumed for three decades to be caused by separate mechanisms, lay instead 
in the relative strength of the opposing immune reactions. Furthermore, reciprocal 
interactions of coexisting donor and recipient leukocyte populations were necessary 
for alloengraftment with both kinds of transplantation (Fig. 4, lower). 
Fig . 4 
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Table V: Differences between conventional bone marrow and organ transplantation (121). 
Bone marrow Organ 
Yes f- Recipient cytoablation"7 No 
Critical f- MHC compatibilitY7 Not Critical 
GVHD f- Principal complication7 Rejection 
Common f- Drug-free state7 Rare 
Tolerance f- Term for success7 "Acceptance""" 
"Note: All differences derive from this therapeutic step which in effect establishes an 
unopposed GVH reaction in the bone marrow recipient whose countervailing immune 
reaction is eliminated. "'Or "operational tolerance". 
After organ transplantation, there is an acute migration of immunogenic multilineage 
"passenger" leukocytes from the graft, selectively at first to host lymphoid organs. In 
the meanwhile, host cells replaced most, but not all, of the passenger leukocytes in 
the graft (Fig. 6). Initially, the coexisting donor and recipient cells in widespread 
organized lymphoid collections generate widespread host-versus-graft (HVG) and 
graft-versus-host (GVH) immune activation that may proceed to reciprocal clonal 
exhaustion-deletion and variable degrees of donor and recipient specific non reactivity 
(i.e., tolerance) (Fig. 5). Maintenance of the acutely induced state require persistence 
of the microchimerism (121-123). The same events in mirror image occur with bone 
marrow engraftment. 
I j 
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With either kind of transplantation, immunosuppression allowed the acute induction to 
proceed by preventing either the donor or recipient cell population from destroying the 
other before the clonal deletion could occur. The organs' passenger leukocytes that 
survive the initial immune reaction migrate secondarily to areas other than the 
lymphoid organs, thereby escaping attack by the host immune system (immune 
indifference) (124). These "sheltered" leukocytes may then "leak" periodically to the 
host lymphoid organs, thus maintaining clonal exhaustion-deletion at a level 
compatible with allograft survival (121 }(Fig. 6). The greatest cell migration occurs 
from the leukocyte-rich liver, accounting for its unusual tolerogenicity; but the same 
events occur after transplantation of all organ grafts. The modulation of the host 
immune response by these donor cells explained the poor discrimination of HLA 
matching for organ transplantation. 
The Immune Reaction to Infectious Microorganisms is the Same as That Against 
Allografts and Xenografts 
In 1974-75, Zinkernagel and Doherty discovered that one of the biologic roles of the 
major histocompatibility complex (MHC) is the adaptive immune response directed 
against intracellular noncytopathic or weakly cytopathic microorganisms (Fig. 7). 
Because the cost of total elimination of all cells infected with this kind of pathogen 
could be the death or invalidism of the host, a means has evolved by which the 
immune response can be terminated by antigen-specific clonal exhaustion-deletion, 
thereby allowing survival of both the microorganism and the host (125-127). Clonal 
deletion is governed by migration and localization of the microorganisms. In the same 
traffic pattern as that of migratory leukocytes, the pathogens move preferentially at 
first to host-organized lymphoid tissues (e.g., lymph nodes, spleen) (128). After either 
an infection or after transplantation, host cytolytic T-Iymphocytes recognize the mobile 
antigen in a MHC-restricted context (121). 
IR<<V 
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Fig. 7 
Thus, a perfect state of allograft acceptance can be compared to a continuously high 
load of non-cytopathic microorganisms that may lead to a pathogen-specific 
immunologic collapse (i.e., an asymptomatic carrier state) (Fig. 7, second panel). At 
the other extreme, acute irreversible rejection may be compared to dramatic, efficient 
control of the pathogen by antigen-specific effector T -cells (Fig. 7, first panel). 
Degrees of chronic rejection of the allograft correspond to variable incomplete clonal 
exhaustion-deletion (Fig. 7, third panel). In mirror image, the infectious disease 
analogy with bone marrow transplantation after pretreatment with cytoablation is 
infection by microorganisms that avoid migration to host lymphoid organs (e.g., rabies 
and wart viruses) and therefore do not induce an efficient immune response (immune 
indifference) (Fig. 7, right). 
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In contrast to the MHC-restricted response to noncytopathic organisms, the response 
to cytopathic microorganisms includes activation of the innate response effectors 
such as interferons, macrophages, gamma/delta T-cells, natural killer (NK) cells, B-
cells that may continue to secrete antibodies without T-cell help, early interleukins and 
phagocytes (127). The principal but probably not the only target of this uncontrollable 
reaction when the organs of lower mammals (e.g., of pigs) are transplanted to 
humans is the galactose a 1-3 galactose epitope (a Gal) found in the Golgi apparatus 
of the cells (129,130). If such discordant animal organs, or even those from more 
closely related species such as baboons are to be transplanted clinically, it will be 
necessary to change the antigeniC profile of the xenograft to one that is recognized by 
the human immune system as a noncytopathic microorganism (i.e., comparable to an 
allograft). Until this is accomplished by the creation of transgenic animals, 
xenotransplantation will not be a viable option. 
Conclusions 
Over the last 40 years, progress in manipulating the mechanisms involved in the 
immune response has steadily increased the probability of allograft acceptance and 
acquired tolerance. However, the penalty has been a variable weakening of the host's 
ability to mount an immunologic response to pathogens, to maintain tumor 
surveillance, or (probably) to carry out other subtle homeostatic functions. Herein lies 
one of the primary challenges to the future of transplantation. Hopefully, from 
continued study of transplantation per se, as well as advances in related fields, more 
effective solutions will be found to overcome the current barriers to allografts or even 
xenografts with minimum perturbation to all other facets of immune function. 
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